Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino) -17-demethoxygeldanamycin (17-DMAG), in rats and dogs: Potential clinical relevance

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 6, 2005, Pages 637-647

  Glaze, Elizabeth R ^a   Lambert, Amy L ^b   Smith, Adaline C ^a   Page, John G ^b   Johnson, William D ^c   McCormick, David L ^c   Brown, Alan P ^d   Levine, Barry S ^d   Covey, Joseph M ^a   Egorin, Merrill J ^e   Eiseman, Julie L ^e   Holleran, Julianne L ^e   Sausville, Edward A ^a   Tomaszewski, Joseph E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c IIT RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

17 AAG; 17 DMAG; Animal toxicity studies; Geldanamycin; Preclinical studies

Indexed keywords

17 (DIMETHYLAMINOETHYLAMINO) 17 DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; NSC 707545; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW TOXICITY; CLINICAL CHEMISTRY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG INFUSION; DRUG TISSUE LEVEL; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL TOXICITY; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LETHALITY; LIVER TOXICITY; MALE; MASS SPECTROMETRY; MONITORING; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SAMPLE; SPECIES; SPLEEN; TISSUE SECTION; TOXICITY; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BODY WEIGHT; BONE MARROW; CLINICAL CHEMISTRY TESTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GALLBLADDER; GASTROINTESTINAL TRACT; HEMATOLOGIC TESTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KIDNEY; LACTAMS, MACROCYCLIC; LONGEVITY; MALE; QUINONES; RATS; RATS, INBRED F344; RECOVERY OF FUNCTION; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 26444462561     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1000-9     Document Type: Article

References (26)

1. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589
2. An WG, Schnur RC, Neckers LM (1997) Depletion of p185erb2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 40:60-64
3. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, Whitesell L (2000) Induction of heat shock factor 1-dependent stress response alters the cytotoxic activity of HSP90-binding agents. Clin Cancer Res 6:3312
4. Banerji U, O'Donnell A, Scurr M, Benson C, Hanwell J, Clark S, Raynaud F, Turner A, Walton M, Workman P, Judson I (2001) Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc Am Soc Clin Oncol 20:82a
5. Borgel SD, Carter JP, Sausville EA, Hollingshead MG (2003) The impact of tumor location on the activity of 17-DMAG (NSC-707545), a water soluble geldanamycin analog. Clin Cancer Res 9(16):6215s
6. DeGeorge JJ, Ahn CH, Andrews PA, Brower ME, Giorgio DW, Goheer MA, Lee-Ham DY, McGuinn WD, Schmidt W, Sun CJ, Tripathi SC (1998) Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 41:173
7. Egorin MJ, Rosen DM, Wolff JH, Callery PS, Musser SM, Eiseman JL (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58:2385
8. 1 mice. Cancer Chemother Pharmacol 47:291
9. 1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49:7
10. Erlichman C, Toft D, Reid J, Sloan J, Atherton P, Adjei A, Ames M, Croghan G (2001) A phase I trial of 17-allyl-aminogeldanamycin in patients with advanced cancer. Proc Am Assoc Cancer Res 42:833
11. Grieshaber CK, Marsoni S (1986) Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep 70:65
12. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003-4009
13. Lowe MC, Davis RD (1984) The current toxicology protocol of the National Cancer Institute. In: Helmann K, Carter SK (eds) Fundamentals of cancer chemotherapy. McGraw-Hill, New York, p 228
14. Munster PN, Tong L, Schwartz L, Larson S, Kenneson K, De La Cruz A, Rosen N, Scher H (2001) Phase I trial of 17-(allylamino)-17-demethoxygeladanamycin (17AAG) in patients (Pts) with advanced solid malignancies. Proc Am Assoc Clin Oncol 20:83a
15. Noker PE, Thompson RB, Smith AC, Tomaszewski JE, Page JG (1999) Toxicity and pharmacokinetics of 17-allylaminogeldanamycin (17-AAG, NSC-330507) in dogs. Proc Am Assoc Cancer Res 40:804
16. Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski JE, Smith A, Rodman L (1997) Comparison of geldanamycin (NSC-122750) and 17-allyaminogeldanamycin (NSC-330507) toxicity in rats. Proc Am Assoc Cancer Res 38:2067
17. Page JG, Noker PE, Tomaszewski JE, Smith AC (1999) Lack of schedule dependent toxicity of 17-allylaminogeldanamycin (17-AAG, NSC-330507) in rats. Proc Am Assoc Cancer Res 40:805
18. Sausville EA, Tomaszewski JE, Ivy P (2003) Clinical development of 17-allylamino,17-demethoxygeldanamycin. Curr Cancer Targets 3:377
19. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273-279
20. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 16(4):249-255
21. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A (2000) Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 17(12):1551-1557
22. Smith DF, Whitesell L, Katsanis E (1998) Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol Rev 50(4):493
23. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM (2002) 17-DMAG (NSC-707545), a water-soluble geldanamycin analog, has superior in vitro and in vivo antitumor activity compared to the hsp90 inhibitor 17-AAG. Eur J Cancer 38(S7):60
24. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993
25. Wilson RH, Takimoto CH, Agnew EB, Morrison G, Grollman F, Thomas RR, Saif MW, Hopkins J, Allegra C, Grochow L, Szabo E, Hamilton JM, Monhan BP, Neckers L, Grem JL (2001) Phase I pharmacological study of 17-(allylamino)-17- demethoxygeldanmycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:82a
26. Workman P (2002) Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38:2189